The urgent need for recommendations on revaccination of hiv-infected children after successful antiretroviral therapy

Clinical Infectious Diseases

Volumn 51, Issue 5, 2010, Pages 634-635

  Rainwater Lovett, Kaitlin ^a   Moss, William J ^b  

^a Department of Epidemiology ^*  (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MEASLES VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; CHILD; EVIDENCE BASED MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MEASLES; MEASLES VACCINATION; PRIORITY JOURNAL; REVACCINATION;

ANTI-HIV AGENTS; CHILD; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; MEASLES-MUMPS-RUBELLA VACCINE; PRACTICE GUIDELINES AS TOPIC;

EID: 77955779571     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655769     Document Type: Letter

References (10)

1. Aurpibul L, Puthanakit T, Sirisanthana T et al. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. Clin Infect Dis 2010; 50: 1415-1418.
2. World Health Organization. Global immunization vision and strategy 2006-2015. Geneva, Switzerland: World Health Organization, 2005. http://www.who.int/vaccines -documents/docspdf05/givs-final-en.pdf. Accessed 26 April 2010., World Health Organization Global immunization vision and strategy 2006-2015. Geneva, Switzerland:World Health Organization,Accessed 26 April 2010.
3. Moss WJ, Scott S, Mugala N, et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. J Infect Dis 2007; 196:347-355.
4. Scott S, Mossong J, Moss WJ, et al. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. Int J Epidemiol 2008; 37:356-367.
5. Otten M, Kezaala R, Fall A, et al. Public-health impact of accelerated measles control in the WHO African Region 2000-03. Lancet 2005; 366:832-839.
6. Centers for Disease Control and Prevention. Global Measles Mortality, 2000-2008. MMWR Morb Mort Wkly Rep 2009; 58:1321-1326.
7. South Africa National Department of Health. Outbreak of measles in the country [press release]. 18 March 2010. http://www.doh.gov .za/mediaroom/index. html. Accessed 23 April 2010.
8. World Health Organization Regional Office for Africa. $8.5 mil needed to fight measles [press release]. 29 March 2010. http://www .afro.who.int/en/zimbabwe/press-materials/ 2260-85-mil-needed-to-fight-measles. html. Accessed 23 April 2010.
9. Sutcliffe CG, van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-489.
10. Bekker V, Scherpbier H, Pajkrt D, et al. Persistent humoral immune defect in highly-active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 2006; 118:e315-e322.